Cantor Fitzgerald Predicts TARA FY2025 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Protara Therapeutics in a research report issued on Monday, March 17th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($1.62) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Several other equities research analysts have also recently issued reports on the stock. Guggenheim reaffirmed a “buy” rating and set a $20.00 target price on shares of Protara Therapeutics in a research note on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Thursday, March 6th. Finally, Lifesci Capital began coverage on Protara Therapeutics in a report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Protara Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.50.

Protara Therapeutics Stock Up 8.8 %

Shares of TARA opened at $4.71 on Wednesday. Protara Therapeutics has a 52-week low of $1.60 and a 52-week high of $10.48. The firm’s fifty day moving average is $4.33 and its two-hundred day moving average is $3.53. The stock has a market cap of $97.17 million, a PE ratio of -1.67 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TARA. Janus Henderson Group PLC purchased a new position in shares of Protara Therapeutics during the 4th quarter worth $11,938,000. Adage Capital Partners GP L.L.C. purchased a new stake in Protara Therapeutics in the 4th quarter valued at about $11,880,000. Toronto Dominion Bank purchased a new stake in Protara Therapeutics in the 4th quarter valued at about $11,030,000. Blackstone Inc. purchased a new stake in Protara Therapeutics in the 4th quarter valued at about $8,870,000. Finally, RA Capital Management L.P. raised its holdings in Protara Therapeutics by 78.9% in the 4th quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock valued at $17,952,000 after buying an additional 1,500,000 shares during the period. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.